. 2017 Apr 11;6:e21350. doi: 10.7554/eLife.21350

Table 2.

Comparison of results on HR activity and drug response of the BRCA1 variants analyzed in this study obtained from previous and this studies.

DOI: http://dx.doi.org/10.7554/eLife.21350.008

	Domain	HR activity (%)						Cisplatin response		Olaparib response
	Domain	Sy et al., 2009	Ransburgh et al. (2010)	Towler et al. (2013)	Bouwman et al. (2013)	Lu et al., 2015	This study	Bouwman et al. (2013)	This study	Bouwman et al. (2013)	This study
Vector		N/A	~10	~9	~20	~18	17.3	S	S	S	S
WT		98	100	100	100	100	100	R	R	R	R
C61G	RING	-	~17	-	-	23.6	21.2	S	S	-	S
C64R	RING	-	-	-	-	-	22.3	-	S	-	S
Y179C		-	-	~95	-	157.1	92.7	-	R	-	R
L246V		-	-	-	-	-	91.5	R	R	-	R
Q356R		-	-	-	-	-	95.5	-	R	-	R
F486L		-	-	-	-	160	95.8	-	R	-	R
R496H		-	-	-	-	-	95.9	-	R	-	R
N550H		-	-	-	-	90.8	88.4	-	R	-	R
L668F		-	-	-	-	96.8	93.6	R	R	-	R
D693N		-	-	-	-	-	111.5	R	R	-	R
V772A		-	-	-	-	110.4	84.5	-	R	-	R
R841W		-	-	-	-	-	98.2	-	R	-	R
P871L		-	-	-	-	-	wt	-	wt	-	wt
M1008I		-	-	-	-	-	99.2	R	R	-	R
E1038G		-	-	-	-	-	wt	-	wt	-	wt
S1040N		-	-	-	-	-	98.0	-	R	-	R
S1101N		-	-	-	-	-	97.3	R	R	-	R
S1140G		-	-	-	-	-	106.2	R	R	-	R
K1183R		-	-	-	-	-	wt	-	wt	-	wt
R1347G		-	-	-	-	-	106.5	-	R	-	R
M1400V	CC	56	-	-	-	-	74.8	R	S	R	S
L1407P	CC	24	-	-	-	-	24	S	S	S	S
M1411T	CC	25	-	-	-	-	26	R	S	R	S
S1512I		-	-	-	-	-	95.3	-	R	-	R
T1561I		-	-	-	-	133.2	102.3	-	R	-	R
S1613G		-	-	-	-	-	wt	-	wt	-	wt
M1628T		-	-	-	-	107	107.6	R	R	-	R
P1637L		-	-	-	-	98.8	99.5	-	R	-	R
5055△G	BRCT	-	-	-	-	-	22.5	-	S	-	S
M1652I	BRCT	-	-	-	-	-	106.2	R	R	-	R
S1655F	BRCT	-	-	-	~30	-	8.4	S	S	-	S
C1697R	BRCT	-	-	-	-	-	8.0	-	S	-	S
R1699Q	BRCT	-	-	-	~45	-	16.9	S	S	S	S
A1708E	BRCT	-	-	-	-	-	10.7	-	S	-	S
S1715R	BRCT	-	-	-	-	-	9.3	-	S	-	S
M1775R	BRCT	36	-	~6	-	-	10.2	-	S	-	S